Kyowa Kirin Advances Ziftomenib in Japan with Phase 2 Trial for Relapsed AML
Event summary
- Kyowa Kirin and Kura Oncology initiated a Japanese Phase 2 trial for ziftomenib in relapsed/refractory NPM1-mutated AML.
- Ziftomenib, approved by the FDA in November 2025, is being tested for potential regulatory approval in Japan.
- The trial is a multicenter, single-arm, open-label study with a primary endpoint of composite complete remission rate.
- Kyowa Kirin plans to file for regulatory approval in Japan upon trial completion.
The big picture
Kyowa Kirin's Phase 2 trial for ziftomenib represents a strategic push into the Japanese market for a drug already approved in the U.S. This move aligns with the broader trend of biotech companies seeking global regulatory approvals to expand market reach. The trial's success could position ziftomenib as a key player in treating relapsed/refractory AML, addressing a significant unmet medical need in Japan.
What we're watching
- Regulatory Pathway
- Whether the Phase 2 trial results will support a successful regulatory filing in Japan.
- Commercial Strategy
- How Kyowa Kirin and Kura Oncology will navigate the global commercialization of ziftomenib.
- Clinical Efficacy
- The efficacy and safety profile of ziftomenib in the Japanese patient population compared to previous trials.
Related topics